Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis [0.03%]
高脂蛋白(a)血症导致慢性脊髓缺血性进行性脊髓病的治疗取得成功
Franz Heigl,Reinhard Hettich,Erich Mauch et al.
Franz Heigl et al.
High concentrations of lipoprotein(a) (Lp(a)) represent an important independent and causal risk factor associated with adverse outcome in atherosclerotic cardiovascular disease (CVD). Effective Lp(a) lowering drug treatment is not availabl...
[Rehabilitation standards for follow-up treatment and rehabilitation of patients with ventricular assist device (VAD)] [0.03%]
心室辅助装置(VAD)植入术后随访治疗康复专家共识
Detlev Willemsen,C Cordes,B Bjarnason-Wehrens et al.
Detlev Willemsen et al.
The increasing use of ventricular assist devices (VADs) in terminal heart failure patients provides new challenges to cardiac rehabilitation physicians. Structured cardiac rehabilitation strategies are still poorly implemented for this spec...
Geleitwort zu "Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation für Patienten mit einem Herzunterstützungssystem (VAD Ventricular Assist Device)" [0.03%]
《心室辅助装置(VAD)患者康复标准的序言》
Hermann Reichenspurner
Hermann Reichenspurner
Bilgen Kurt,Muhidien Soufi,Alexander Sattler et al.
Bilgen Kurt et al.
Lipoprotein(a) (Lp(a)) was first described by K. Berg and is known for more than 50 years. It is an interesting particle and combines the atherogenic properties of low-density lipoprotein (LDL)-cholesterol as well as the thrombogenic proper...
Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects [0.03%]
脂蛋白(Lp(a))高血脂作为心血管风险因素的病理生理方面
Gerd Schmitz,Evelyn Orsó
Gerd Schmitz
Lipoprotein (a) [Lp(a)] is a modified LDL particle with an additional apolipoprotein [apo(a)] protein covalently attached by a thioester bond. Multiple isoforms of apo(a) exist that are genetically determined by differences in the number of...
[Editorial] [0.03%]
【编者按】
Dieter Horstkotte
Dieter Horstkotte
Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias [0.03%]
难治性高脂血症血液净化治疗的指征
P Grützmacher,C Kleinert,C Dorbath et al.
P Grützmacher et al.
Lipid apheresis is at present well established in routine treatment of diverse hyperlipoproteinemias refractory to conventional dietary and medical regimens, especially in countries with high medical and socioeconomic standards. Severe fami...
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease [0.03%]
长期血脂吸附治疗严重高胆固醇血症或Lp（a）脂蛋白血症并进行性心血管疾病的临床疗效
Franz Heigl,Reinhard Hettich,Norbert Lotz et al.
Franz Heigl et al.
Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are established causal risk factors for cardiovascular disease (CVD). Efficacy, safety, and tolerability of lipoprotein apheresis (LA) were investigated in 118 patients ...
K-P Mellwig,C Schatton,B Biermann et al.
K-P Mellwig et al.
The clinical relevance of lipoprotein(a) (Lp(a)) as a cardiovascular risk factor is currently underestimated. The aim of our study was to assess the influence of increased Lp(a) values on the development and severity of coronary artery dise...
[Extracardiac manifestation of elevated lipoprotein(a) levels--cumulative incidence of peripheral arterial disease and stenosis of the carotid artery] [0.03%]
脂蛋白(a)升高的非心脏表现-外周动脉病和颈动脉狭窄的累积患病率
Frank van Buuren,Julia Alexia Sommer,Tanja Kottmann et al.
Frank van Buuren et al.
Background: Elevated lipoprotein(a) (Lp(a)) levels are an accepted risk factor for coronary heart disease. The role of Lp(a) in the development of extracardiac arteriosclerosis like peripheral arterial disease (PAD) and s...